Title and Organization:
Matthew Lawrence is CEO of RxGen, a translational research company devoted to advancing health by accelerating the development of new therapeutics for central nervous system, ophthalmic, cardiovascular, and metabolic diseases. Matthew applies a clinical perspective to the judicious development and utilization of preclinical models to validate promising interventions and reduce the risk of costly clinical failures. Core disease pathophysiology and transformational therapeutic strategies are a recurring focus, including the biology of aging and its relation to age-associated conditions such as Alzheimer’s disease. Matthew maintains an adjunct appointment in the Department of Comparative Medicine at Yale and works closely with a diversely experienced internal team and range of industry and academic groups to develop small molecule, biologic, and gene and cell therapy candidates in programs funded by the NIH, philanthropies, venture capital, and pharmaceutical companies. Matthew received his bachelor’s degree in earth and planetary sciences and biology from Harvard, his PhD in Neuroscience from Stanford, and his MD from Yale; he completed his internal medicine internship at the University of Hawaii and his ophthalmology residency at the Massachusetts Eye and Ear Infirmary. Matthew is a Fellow in the fourth class of the Health Innovators Fellowship and a member of the Aspen Global Leadership Network.